Screening for a rare enzyme disease in patients with lung scarring
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Lungs & breathing clinical trials.
This study checks if people with certain lung changes (called interstitial lung disease) might have a rare enzyme deficiency that can cause lung and other organ problems. Finding this could lead to better treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung disease that shows ground-glass patterns on a CT scan
- You have one of these: an enlarged spleen, had your spleen removed, low blood platelets, low HDL cholesterol, or parents who are blood relatives
- You are willing to give written permission to join the study
- You are covered by national health insurance (excluding AME)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to find early signs of lung scarring (interstitial lung disease) in people with rheumatoid arthritis or scleroderma using a blood test and a lung ultrasound. It may help detect lung problems earlier, when treatment could be more effective.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This screening study looks for two rare inherited conditions—Gaucher disease and acid sphingomyelinase deficiency—in people who have an enlarged spleen and low blood platelets. By identifying these conditions early, it may help manage symptoms and improve quality of life.
This trial is a study database that collects information from adults who have other illnesses that can increase the risk of developing interstitial lung disease (lung scarring). It may help researchers better understand who is at risk and how outcomes change over time.
This study looks at special chemicals in the blood (metabolites) from people with both lung scarring and high lung blood pressure. It aims to learn how these chemicals change with or without treatment for the lung blood pressure.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Splenomegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.